Trial Profile
Real-World Assessment of Long-Term Infliximab Therapy for Psoriasis
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 10 May 2022
Price :
$35
*
At a glance
- Drugs Infliximab (Primary)
- Indications Plaque psoriasis
- Focus Therapeutic Use
- Acronyms REALITY
- Sponsors Merck & Co; Merck Sharp & Dohme; Schering-Plough
- 25 Mar 2014 Results presented at the 72nd Annual Meeting of the American Academy of Dermatology.
- 26 Oct 2012 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 17 Dec 2010 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.